Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 83 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Epidemiol Health > Volume 39; 2017 > Article
Original Article
Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia
Getachew Mebrahtu Welay1, Kefyalew Addis Alene2, Berihun Assefa Dachew2,3orcid
Epidemiol Health 2016;39:e2017001.
DOI: https://doi.org/10.4178/epih.e2017001
Published online: December 28, 2016
  • 15,959 Views
  • 378 Download
  • 16 Web of Science
  • 18 Crossref
  • 17 Scopus

1Aksum University, Shire Campus, Shire, Ethiopia

2Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

3The University of Queensland, School of Public Health, Herston, QLD, Australia

Correspondence: Berihun Assefa Dachew  Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia  E-mail: berihunassefa21@gmail.com
• Received: December 17, 2016   • Accepted: December 28, 2016

©2017, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • OBJECTIVES
    Poor treatment outcomes of visceral leishmaniasis (VL) are responsible for the high mortality rate of this condition in resource-limited settings such as Ethiopia. This study aimed to identify the proportion of poor VL treatment outcomes in northwest Ethiopia and to evaluate the determinants associated with poor outcomes.
  • METHODS
    A hospital-based retrospective study was conducted among 595 VL patients who were admitted to Kahsay Abera Hospital in northwest Ethiopia from October 2010 to April 2013. Data were entered into Epi Info version 7.0 and exported to SPSS version 20 for analysis. Bivariate and multivariate logistic regression models were fitted to identify the determinants of VL treatment outcomes. Adjusted odds ratio (aORs) with 95% confidence intervals (CIs) were used, and p-values <0.05 were considered to indicate statistical significance.
  • RESULTS
    The proportion of poor treatment outcomes was 23.7%. Late diagnosis (≥29 days) (aOR, 4.34; 95% CI, 2.22 to 8.46), severe illness at admission (inability to walk) (aOR, 1.63; 95% CI, 1.06 to 2.40) and coinfection with VL and human immunodeficiency virus (HIV) (aOR, 2.72; 95% CI, 1.40 to 5.20) were found to be determinants of poor VL treatment outcomes.
  • CONCLUSIONS
    Poor treatment outcomes, such as death, treatment failure, and non-adherence, were found to be common. Special attention must be paid to severely ill and VL/HIV-coinfected patients. To improve VL treatment outcomes, the early diagnosis and treatment of VL patients is recommended.
Visceral leishmaniasis (VL) is the most severe vector-borne protozoan disease caused by Leishmania donovani, and is transmitted by the bite of female Phlebotomus sand flies [1,2]. VL is a global health problem, imposing an estimated disease burden of 1.98 million disability-adjusted life years and 20,000 to 40,000 deaths per annum around the world [1].
Ninety percent of the global burden of VL occurs in India, Bangladesh, Brazil, Sudan, South Sudan, and Ethiopia [3-5]. Although VL is treatable, in sub-Saharan Africa, mortality associated with VL is still high. This is directly or indirectly related to poor treatment outcomes, which occur for a number of reasons [6,7].
Ethiopia is a country highly affected by VL, with 1,860 cases of VL reported annually and an estimated annual incidence of VL ranging from 3,700 to 7,400 cases [8].
In Ethiopia, the northwest lowland areas (Metema and Humera districts) bordering Sudan are the most important endemic foci of VL, accounting for 60% of the VL burden in the country [9,10]. This region also has the highest burden of VL/human immunodeficiency virus (HIV) coinfection in the world, with the HIV prevalence among VL patients ranging from 19 to 41% [10].
Poor treatment outcomes for VL have become a challenging public health problem in Ethiopia, particularly in the northwest region of the country. One of the greatest concerns regarding VL is its high fatality rate, which reaches almost 100% among non-treated symptomatic patients, in contrast to a 10% fatality rate among VL patients who undergo treatment.
Data on treatment outcomes and the determinants thereof would enable policymakers, clinicians, and funding organizations to establish priorities for addressing VL incidence and mortality in the northwestern sub-region of Ethiopia. However, although there have been a few studies on VL/HIV coinfection, the proportion of poor treatment outcomes among VL patients and the determinants of treatment failure have not been well investigated in the study area. Hence, this study aimed to assess the proportion and determinants of poor treatment outcomes among VL patients at Kahsay Abera Hospital in northwest Ethiopia.
Study design and setting
A hospital-based retrospective study was conducted at Kahsay Abera Hospital in northwestern Ethiopia. This hospital is a general facility where all diseases are treated. There is a leishmaniasis treatment center within the hospital, which is located in Humera, one of the most important VL endemic foci in the country. Humera, at an elevation of 600 m above sea level, is characterized by a very harsh environment, with an annual temprature ranging from 27 to 45°C and rainfall ranging from 900 to 1,800 mm per annum. Humera is one of Ethiopia’s most fertile agricultural zones, with large-scale farming of cash crops such as sesame, maize, cotton, and sorghum. Since 1970, Humera has undergone an extensive program of agricultural development, with a consequent influx of migrant workers, which has led to a rapid increase in the number of VL cases. Migrants travel to Humera to work in the sowing and harvest seasons, mainly from October to February and from May to July. Seasonal agricultural work attracts approximately 500,000 migrant laborers each year from non-endemic parts of Tigray and neighboring regions [11].
A clinical case of VL is defined as a person who presents with fever for more than 2-week and an enlarged spleen (splenomegaly) and/or enlarged lymph nodes (lymphadenopathy), or symptoms such as loss of weight, anemia, or leukopenia, while living in or having recently travelled to a known endemic area for VL. Diagnosis of VL at Kahsay Abera Hospital is performed according to the standardized Médecins Sans Frontières (MSF) and Ethiopian Ministry of Health guidelines using a positive rK39 rapid diagnostic test (DiaMed-IT-Leish, DiaMed, Cressier, Switzerland) and the microscopic examination of aspirates from the spleen [12]. The diagnosis has a high specificity, but the sensitivity of the microscopy varies (93 to 99% for the spleen, 53 to 86% for bone marrow, and 53 to 65% for lymph node aspirate) [13].
Treatment is normally provided only after the presence of the disease is confirmed based on a clinical examination and labora2tory tests. Sodium stibogluconate monotherapy is administered through intramuscular injections of 20 mg/kg/d for 30 days. The treatment regimen at the hospital follows the national guidelines.
Definitions of terms in visceral leishmaniasis cases
An initial cure was defined as a patient showing improvement in signs and symptoms after 30 days of standard treatment (fever resolution, hemoglobin increase, weight gain, and spleen size regression), the absence of parasites in smears, and a negative test-of-cure (TOC) culture. In the current study, we were not able to assess whether the cure was definitive at a 6-month follow-up examination, since VL patients are often migrants from rural communities and are difficult to trace once they are discharged from the hospital. Poor treatment outcomes were defined as death, treatment failure, and non-adherence. Initial treatment failure was defined as a positive TOC culture (parasitological failure) and/or clinical signs/symptoms that persisted after 30 days of standard treatment. Functional status was defined as an individual’s ability to perform the normal daily activities required to meet basic needs, fulfill his or her usual roles, and maintain health and well-being.
Inclusion and exclusion criteria
All VL patients at the Kahsay Abera Hospital Leishmaniasis Treatment Center who underwent anti-leishmaniasis treatment from October 2010 to April 2013 were included in this study. More recent data were not included, as the proper data-handling format was not completely implemented at the hospital after the MSF project was phased out. A total of 890 VL patients were registered during the study period, of whom 595 patients were included. Those who were transferred out to other health institutions for better management and those for whom the available information was incomplete were excluded from the study.
Data collection
Demographic, clinical, immunological, and laboratory profile data were collected using a prepared data extraction tool. Four trained health professionals collected the data from the patients’ charts after confirming that the records were complete.
Treatment outcomes and patient characteristics were collected from the medical registry casebook and VL patient charts, respectively, and transferred to the data extraction tool after the completion of 30 days of standard treatment.
A good treatment outcome was considered to be cure of the disease as measured by both a laboratory test (a negative TOC culture at the end of 30 days of standard treatment) and clinical signs and symptoms (weight gain, normal body temperature, and regressed spleen). Non-adherence (patients who were lost to follow-up or did not pick up their drugs for more than 15 days), treatment failure (non-response or failure to decrease the parasitological grade after a 30-day course of the treatment regimen) and death due to visceral leishmaniasis were considered to be poor treatment outcomes [14].
Data analysis
Data were cleaned and entered into a computer using Epi Info version 7 (Centers for Disease Control and Prevention, Atlanta, GA, USA) and exported to SPSS version 20 (IBM Corp., Armonk, NY, USA) for analysis. Both descriptive and analytical statistical procedures were utilized. Descriptive statistics such as percentages, mean values, and standard deviations were used to present our results. Binary logistic regression was used to identify factors associated with poor treatment outcomes among VL patients. Bivariate analysis was performed to identify the association of each independent variable with VL treatment outcomes. Variables with p-values <0.2 in the bivariate analysis were entered into the multivariate analysis to identify the determinants of poor outcomes while controlling for the possible effect of confounds. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were used to determine the strength of associations, and variables with a p-value <0.05 in the final model were taken as significant determinants of treatment outcomes. The goodness-of-fit of the model was tested using the Hosmer–Lemeshow test for the full model (p>0.05).
Ethics approval and consent to participate
Ethical clearance was obtained from the Ethical Review Committee of the Institute of Public Health, University of Gondar. A permission letter was also obtained from the Tigray Regional State Health Bureau to review pre-existing health records. To ensure confidentiality, patients’ names were not extracted from the records.
Demographic characteristics
A total of 595 VL patient records were included in the analysis. The patients’ mean age was 25.9±9.6 years, and a majority of them (535, 89.9%) were in the age group of 16 to 45 years. Almost half of them (284, 47.7%) were residents of the district, and one-third (220, 37.0%) were migrants from nearby districts and zones. The majority of patients (555, 93.3%) were males (Table 1).
Baseline clinical and laboratory profiles of the patients
The mean time between clinical manifestations and hospital admission was 25.82 days, ranging from 2 to 365 days. One-fourth of VL patients (141, 23.7%) had a delay in diagnosis and treatment. The mean hospital stay of patients during treatment was 23.6±10.5 days. The mean hemoglobin level of patients was 8.98±4.26 g/dL (Table 2).
Determinants of poor visceral leishmaniasis treatment outcomes
The proportion of poor VL treatment outcomes was found to be 23.7%, of which 12.4% were death, 5.7% were treatment failure, and 5.6% were non-adherence.
Delayed diagnosis and treatment, inability to walk at hospitalization, baseline platelet count, and tuberculosis and HIV coinfections were found to be significantly associated with poor VL treatment outcomes in the univariate analysis.
However, in the multivariate logistic regression analysis, only delayed diagnosis and treatment, inability to walk at hospitalization, and VL/HIV coinfection remained significantly and independently associated with poor VL treatment outcomes.
VL patients who were admitted to the treatment center late (≥29 days after the onset of symptoms) were 4.34 times more likely to have poor treatment outcomes than patients who were admitted early (<13 days) (aOR,4.34; 95% CI, 2.22 to 8.46).
VL patients who were unable to walk (severely ill) at admission were at a 1.63 times greater risk of poor treatment outcomes than those who were able to walk (moderately ill) (aOR, 1.63; 95% CI, 1.06 to 2.40). Similarly, HIV coinfected VL patients were at a 2.72 times greater risk of poor treatment outcomes than non-coinfected VL patients (aOR, 2.72; 95% CI, 1.40 to 5.20) (Table 3).
Copious data on treatment outcomes and their determinants among VL patients are necessary for national control, prevention, and elimination of VL.
In comparison with other similar studies conducted elsewhere in Ethiopia (18.5%) [15], poor VL treatment outcomes were found to be common (23.7%) in the current study, which was conducted in northwest Ethiopia. This proportion of poor outcomes is also higher than that found in a study conducted in Brazil (2%) [16]. This could be due to differences in design, setting, and the type of subjects involved in the study.
However, the proportion found in this study was lower than that found in a study conducted in another part of Ethiopia (31.6%) [17]. This discrepancy may be due to differences in the study subjects, as the previous study was performed on HIV-VL coinfected patients, and VL/HIV coinfection increases the likelihood of poor treatment outcomes. However, the results of the present study correspond to those obtained in West Bengal, India (22.7%) [14] and Peru (24.4%) [18].
Although the current study used secondary data and was limited in the possible variables it could identify that might have had an effect on treatment outcomes, this study identified late presentation and admission to the treatment center, severe illness as measured by the functional status of patients at admission, and HIV/VL coinfection as determinants of poor VL treatment outcomes.
VL patients who were admitted to the treatment center with a delay of more than a month (≥29 days) from the onset of symptoms were four times more likely to have poor treatment outcomes than patients who presented and were admitted earlier. Delays in diagnosis and treatment are a bottleneck challenge in migrant and rural communities working in remote agricultural areas where health facilities are limited and day laborers lack knowledge and awareness of the need for early admission to a health facility after the onset of clinical symptoms. The negative effects of delays in diagnosis and treatment on outcomes have been reported in Peru [18], Georgia [19], and South Sudan [20]. This suggests a need for increased community awareness of the necessity of visiting a health institution as soon as the first clinical symptoms of VL manifest.
In addition, further analysis indicated that VL patients who were unable to walk at admission (severely ill) were 1.63 times more likely to have poor treatment outcomes as compared to those who were able to walk (moderately ill). This result is comparable to the findings of a study conducted in Brazil. This association is due to the fact that clinically deteriorated patients may come in at a critical stage, resulting in poor treatment outcomes and a poor prognosis [5].
This study also found that VL/HIV coinfection was a determinant of poor treatment outcomes, as VL/HIV-coinfected patients were 2.72 times more likely to have poor treatment outcomes than non-coinfected patients. This can be easily explained by the pathophysiology of the two diseases, as both HIV and VL lead to a compromised immune status in the patient and poor treatment outcomes [5,16,21].
This study has several limitations that should be considered when interpreting its results. The data were retrospectively extracted from patients’ medical records, and some important variables such as parasite load, total leukocyte count, and CD4 count were inadequately recorded and were not included in the analysis. Moreover, a few patients were discharged and considered cured before the full treatment course was completed and/or without a TOC culture. In addition to this, only 595 of the 890 VL patients were included in the study, while the remaining patients were excluded from the study because they were referred to other facilities or their data files were missing. This may have led to bias and underestimation or overestimation of the associations with treatment outcomes if the patient exclusion conditions were related to treatment outcomes.
Poor VL treatment outcomes, defined as death, treatment failure, or non-adherence, were found to be common among VL patients. Late presentation and admission to the treatment center, inability to walk at admission (severe illness), and HIV/VL coinfection were determinants of poor VL treatment outcomes. Hence, VL treatment outcomes would be improved if patients sought care at a health institution at the earliest manifestation of clinical symptoms, and if special attention were given to severely ill and VL/HIV-coinfected patients. In addition, prioritizing treatment for communities in which VL is endemic and VL patient education are advisable. Moreover, a prospective follow-up study design would be helpful for determining other important variables related to VL treatment outcomes.
The authors would like to thank the University of Gondar for providing ethical clearance and Kahsay Abera Hospital for material support. The authors are indebted to the Tigray Regional Health Bureau for the letter of permission to Kahsay Abera Hospital. The authors would also like to acknowledge the data collectors and hospital staff members for their dedicated cooperation, which made the study possible.

The authors have no conflicts of interest to declare for this study.

Table 1.
Demographic characteristics of visceral leishmaniasis patients at Kahsay Abera Hospital, Humera, Ethiopia, 2010-2013 (n=595)
Characteristics Frequency %
Age (yr)
 ≤15 29 4.9
 16-45 535 89.9
 ≥46 31 5.2
Sex
 Male 555 93.3
 Female 40 6.7
Residence
 Rural 400 67.2
 Urban 195 32.8
Migration status
 Migrants 220 37.0
 Residents 284 47.7
 New settlers 91 15.3
Table 2.
Clinical and laboratory profiles of visceral leishmaniasis patients at Kahsay Abera Hospital, Humera, Ethiopia, 2010-2013 (n=595)
Characteristics Frequency %
Time elapsed before diagnosis (d)
 <13 107 18.0
 14-28 347 58.3
 ≥29 141 23.7
General condition of patients
 Able to walk 357 60.0
 Unable to walk 238 40.0
Fever
 No 28 4.7
 Yes 567 95.3
Weight loss
 No 64 10.8
 Yes 531 89.2
Jaundice
 No 537 90.3
 Yes 58 9.7
Splenomegaly
 No 98 16.5
 Yes 497 83.5
Anemia
 No 173 29.1
 Yes 422 70.9
Hemoglobin (g/dL)
 <7.9 279 46.9
 8.0-10.9 102 17.1
 ≥11.0 214 36.0
Platelet count (cells/mm3)
 <85,000 265 44.5
 ≥85,000 330 55.5
BMI (kg/m2)
 <18.5 511 85.9
 ≥18.5 84 14.1
Tuberculosis
 No 534 89.7
 Yes 61 10.3
Malaria
 No 469 78.8
 Yes 126 21.2
HIV status
 No 546 91.2
 Yes 49 8.2

BMI, body mass index; HIV, human immunodeficiency virus.

Table 3.
Bivariate and multivariate logistic regression analysis of the factors associated with poor treatment outcomes among visceral leishmaniasis patients at Kahsay Abera Hospital, Humera, Ethiopia, 2010-2013 (n=595)
Variables Good treatment outcome (cure) Poor treatment outcome cOR (95% CI) aOR (95% CI)
Age (yr)
 ≥46 17 14 3.15 (1.01,9.90) 3.00 (0.80,10.50)
 16-45 414 121 1.12 (0.45,2.80) 1.25 (0.45,3.50)
 <15 23 6 1.00 1.00
Duration prior to diagnosis (d)
 ≥29 76 65 5.25 (2.78, 9.90) 4.34 (2.20,8.46)*
 14-28 286 61 1.30 (0.70, 2.40) 1.20 (0.60, 2.20)
 <13 92 15 1.00 1.00
General condition
 Unable to walk 167 71 1.74 (1.20, 2.50) 1.63 (1.06, 2.40)*
 Able to walk 287 70 1.00 1.00
Weight loss
 Yes 400 131 1.70 (0.80,3.50) 1.60 (0.70, 3.40)
 No 54 10 1.00 1.00
Hepatomegaly
 Yes 15 9 2.00 (0.85, 4.66) 1.64 (0.60, 4.20)
 No 439 132 1.00 1.00
Hemoglobin (g/dL)
 <7.9 210 69 1.40 (0.89, 2.14) 0.90 (0.50,1.45)
 8.0-10.9 71 31 1.80 (1.07,3.16) 1.20 (0.64, 2.15)
 ≥11.0 173 41 1.00 1.00
Platelet count (cells/mm3)
 <85,000 188 77 1.60 (1.10, 2.40) 1.38 (0.87, 2.20)
 ≥85,000 266 64 1.00 1.00
Tuberculosis
 Yes 40 21 1.80 (1.03, 3.20) 1.39 (0.73, 2.67)
 No 414 120 1.00 1.00
HIV/AIDS
 Yes 26 23 3.20 (1.70, 5.80) 2.72 (1.40, 5.20)*
 No 428 118 1.00 1.00

cOR, crude odds ratio; aOR, adjusted odds ratio; CI, confidence interval; HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome.

* p<0.05.

  • 1. van Griensven J, Zijlstra EE, Hailu A. Visceral leishmaniasis and HIV coinfection: time for concerted action. PLoS Negl Trop Dis 2014;8:e3023.ArticlePubMedPMC
  • 2. Perry D, Dixon K, Garlapati R, Gendernalik A, Poché D, Poché R. Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011. Am J Trop Med Hyg 2013;88:778-784.ArticlePubMedPMC
  • 3. Huda MM, Chowdhury R, Ghosh D, Dash AP, Bhattacharya SK, Mondal D. Visceral leishmaniasis-associated mortality in Bangladesh: a retrospective cross-sectional study. BMJ Open 2014;4:e005408.ArticlePubMedPMC
  • 4. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 2013;26:1-9.ArticlePubMed
  • 5. Mourão MV, Toledo Jr A, Gomes LI, Freire VV, Rabello A. Parasite load and risk factors for poor outcome among children with visceral leishmaniasis. A cohort study in Belo Horizonte, Brazil, 2010-2011. Mem Inst Oswaldo Cruz 2014;109:147-153.ArticlePubMedPMCPDF
  • 6. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009;3:e412.ArticlePubMedPMC
  • 7. van den Bogaart E, Berkhout MM, Nour AB, Mens PF, Talha AB, Adams ER, et al. Concomitant malaria among visceral leishmaniasis in-patients from Gedarif and Sennar States, Sudan: a retrospective case-control study. BMC Public Health 2013;13:332.ArticlePubMedPMCPDF
  • 8. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:e35671.ArticlePubMedPMC
  • 9. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 2010;15:848-855.ArticlePubMed
  • 10. Endris M, Takele Y, Woldeyohannes D, Tiruneh M, Mohammed R, Moges F, et al. Bacterial sepsis in patients with visceral leishmaniasis in Northwest Ethiopia. Biomed Res Int 2014;2014:361058.ArticlePubMedPMCPDF
  • 11. Argaw D, Mulugeta A, Herrero M, Nombela N, Teklu T, Tefera T, et al. Risk factors for visceral leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia. PLoS Negl Trop Dis 2013;7:e2543.ArticlePubMedPMC
  • 12. Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, et al. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan. Trop Med Int Health 2015;20:1674-1684.ArticlePubMed
  • 13. Federal Ministry Health of Ethiopia. Guidlines for diagnosis, treatment and prevention of leishmaniasis in Ethiopia. 2nd ed. Addis Ababa: Ministry of Health; 2013. p 1-88.
  • 14. Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, et al. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 2010;83:357-364.ArticlePubMedPMC
  • 15. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health 2003;8:733-739.ArticlePubMed
  • 16. Santos MA, Marques RC, Farias CA, Vasconcelos DM, Stewart JM, Costa DL, et al. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev Soc Bras Med Trop 2002;35:629-633.ArticlePubMedPDF
  • 17. Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis 2014;8:e2875.ArticlePubMedPMC
  • 18. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008;46:223-231.ArticlePubMedPDF
  • 19. Kajaia M, Morse DL, Kamkamidze G, Butsashvili M, Chubabria G, Zenaishvili O, et al. Risk factors for relapse of visceral leishmaniasis in Georgia. Trop Med Int Health 2011;16:186-192.ArticlePubMed
  • 20. Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004;38:612-619.ArticlePubMedPDF
  • 21. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008;46:1702-1709.ArticlePubMedPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia
      Muluneh Ademe, Yaneth Osorio, Rawliegh Howe, Saba Atnafu, Tadele Mulaw, Helina Fikre, Bruno L. Travi, Asrat Hailu, Peter C. Melby, Tamrat Abebe
      Tropical Medicine and Infectious Disease.2023; 8(1): 36.     CrossRef
    • Fever of unknown origin and splenomegaly: a case report of visceral leishmaniasis diagnosed by metagenomic next-generation sequencing
      Lan-Qing Li, Yiju He, Ting Liu, Jing Zhou, En-Qiang Chen
      Future Microbiology.2023; 18(11): 699.     CrossRef
    • Trend of Visceral Leishmaniasis at Medicine Sans Frontier’s Abdurafi Treatment Center, West Armachiho District, Ethiopia, 2009-2015, a retrospective descriptive analysis
      Sisay Awoke, Sefonias Getachew, Yimer Seid, Tatek Bogale
      Journal of Interventional Epidemiology and Public Health.2022;[Epub]     CrossRef
    • Zoonotic Diseases in the eastern region of the Iraqi capital, between 2010-2016
      A S Barrak, O A Saeed, MTA Mohammed
      IOP Conference Series: Earth and Environmental Science.2021; 779(1): 012008.     CrossRef
    • Inequalities of visceral leishmaniasis case-fatality in Brazil: A multilevel modeling considering space, time, individual and contextual factors
      Gláucia Cota, Astrid Christine Erber, Eva Schernhammer, Taynãna Cesar Simões, Alberto Novaes Ramos
      PLOS Neglected Tropical Diseases.2021; 15(7): e0009567.     CrossRef
    • Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
      Aschalew Tamiru, Rezika Mohammed, Saba Atnafu, Girmay Medhin, Asrat Hailu, Peter C. Melby
      PLOS Neglected Tropical Diseases.2021; 15(8): e0009713.     CrossRef
    • Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects
      O.F. Davies-Bolorunduro, O. Osuolale, S. Saibu, I.A. Adeleye, N.S. Aminah
      Heliyon.2021; 7(8): e07710.     CrossRef
    • Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis
      Mehdi Mohebali, Yonas Yimam
      BMC Infectious Diseases.2020;[Epub]     CrossRef
    • Incidence of Mortality and Its Predictors Among Adult Visceral Leishmaniasis Patients at the University of Gondar Hospital: A Retrospective Cohort Study


      Yigizie Yeshaw, Adino Tesfahun Tsegaye, Solomon Gedlu Nigatu
      Infection and Drug Resistance.2020; Volume 13: 881.     CrossRef
    • Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations
      Kyung-Hwa Baek, Laura Piel, Thibault Rosazza, Eric Prina, Gerald F. Späth, Joo Hwan No
      Pathogens.2020; 9(5): 393.     CrossRef
    • Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening
      S. Lamotte, N. Aulner, G. F. Späth, E. Prina
      Scientific Reports.2019;[Epub]     CrossRef
    • Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia
      Kidu Gidey, Desalegn Belay, Berhane Yohannes Hailu, Tesfaye Dessale Kassa, Yirga Legesse Niriayo
      BioMed Research International.2019; 2019: 1.     CrossRef
    • Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
      Dinesh Mondal, Prakash Ghosh, Rajashree Chowdhury, Christine Halleux, Jose A. Ruiz-Postigo, Abdul Alim, Faria Hossain, Md Anik Ashfaq Khan, Rupen Nath, Malcolm S. Duthie, Axel Kroeger, Greg Matlashewski, Daniel Argaw, Piero Olliaro
      Frontiers in Microbiology.2019;[Epub]     CrossRef
    • Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia
      Helina Fikre Tamiru, Yohana James Mashalla, Rezika Mohammed, Gloria Thupayagale Tshweneagae
      BMC Infectious Diseases.2019;[Epub]     CrossRef
    • The criminal association of Leishmania parasites and viruses
      Matteo Rossi, Nicolas Fasel
      Current Opinion in Microbiology.2018; 46: 65.     CrossRef
    • Leishmaniasis in Ethiopia: A systematic review and meta-analysis of prevalence in animals and humans
      Ayalew Assefa
      Heliyon.2018; 4(8): e00723.     CrossRef
    • Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis
      Eyob Alemayehu Gebreyohannes, Akshaya Srikanth Bhagvathula, Tadesse Melaku Abegaz, Mohammed Assen Seid
      Infectious Diseases of Poverty.2018;[Epub]     CrossRef
    • A preliminary survey of major diseases of ruminants and management practices in Western Tigray province, northern Ethiopia
      Getachew Mebrahtu Welay, Dawit Gebremichael Tedla, Gebreyohans Gebru Teklu, Shishay Kahsay Weldearegay, Mearg Belay Shibeshi, Haftom Hadush Kidane, Berhe Beyene Gebrezgiabher, Teklehaymanot Huluf Abraha
      BMC Veterinary Research.2018;[Epub]     CrossRef


    Epidemiol Health : Epidemiology and Health